|
Gene: LOX |
Gene summary for LOX |
Gene summary. |
Gene information | Species | Human | Gene symbol | LOX | Gene ID | 4015 |
Gene name | lysyl oxidase | |
Gene Alias | AAT10 | |
Cytomap | 5q23.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | B7ZAJ4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4015 | LOX | P4T-E | Human | Esophagus | ESCC | 3.52e-03 | 3.03e-01 | 0.1323 |
4015 | LOX | P8T-E | Human | Esophagus | ESCC | 7.98e-04 | 2.02e-01 | 0.0889 |
4015 | LOX | P16T-E | Human | Esophagus | ESCC | 2.51e-10 | 3.41e-01 | 0.1153 |
4015 | LOX | P17T-E | Human | Esophagus | ESCC | 1.22e-04 | 5.42e-01 | 0.1278 |
4015 | LOX | P23T-E | Human | Esophagus | ESCC | 8.95e-05 | 2.66e-01 | 0.108 |
4015 | LOX | P32T-E | Human | Esophagus | ESCC | 7.80e-22 | 9.89e-01 | 0.1666 |
4015 | LOX | P37T-E | Human | Esophagus | ESCC | 9.32e-18 | 6.36e-01 | 0.1371 |
4015 | LOX | P42T-E | Human | Esophagus | ESCC | 9.84e-07 | 3.99e-01 | 0.1175 |
4015 | LOX | P44T-E | Human | Esophagus | ESCC | 2.72e-04 | 6.69e-01 | 0.1096 |
4015 | LOX | P52T-E | Human | Esophagus | ESCC | 1.68e-10 | 5.54e-01 | 0.1555 |
4015 | LOX | P61T-E | Human | Esophagus | ESCC | 3.95e-07 | 2.81e-01 | 0.099 |
4015 | LOX | P62T-E | Human | Esophagus | ESCC | 1.12e-04 | 2.69e-01 | 0.1302 |
4015 | LOX | P74T-E | Human | Esophagus | ESCC | 1.39e-02 | 1.59e-01 | 0.1479 |
4015 | LOX | P76T-E | Human | Esophagus | ESCC | 1.70e-17 | 7.18e-01 | 0.1207 |
4015 | LOX | P89T-E | Human | Esophagus | ESCC | 1.46e-19 | 1.93e+00 | 0.1752 |
4015 | LOX | P91T-E | Human | Esophagus | ESCC | 1.63e-05 | 1.14e+00 | 0.1828 |
4015 | LOX | P130T-E | Human | Esophagus | ESCC | 2.01e-15 | 5.56e-01 | 0.1676 |
4015 | LOX | C21 | Human | Oral cavity | OSCC | 1.02e-16 | 8.01e-01 | 0.2678 |
4015 | LOX | C30 | Human | Oral cavity | OSCC | 8.45e-06 | 6.01e-01 | 0.3055 |
4015 | LOX | C43 | Human | Oral cavity | OSCC | 1.19e-30 | 5.57e-01 | 0.1704 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:001003827 | Esophagus | ESCC | response to metal ion | 208/8552 | 373/18723 | 5.02e-05 | 3.90e-04 | 208 |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:0030041110 | Esophagus | ESCC | actin filament polymerization | 114/8552 | 191/18723 | 6.46e-05 | 4.92e-04 | 114 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:000806419 | Esophagus | ESCC | regulation of actin polymerization or depolymerization | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
GO:00302167 | Esophagus | ESCC | keratinocyte differentiation | 86/8552 | 139/18723 | 8.53e-05 | 6.19e-04 | 86 |
GO:00456046 | Esophagus | ESCC | regulation of epidermal cell differentiation | 41/8552 | 58/18723 | 1.00e-04 | 7.10e-04 | 41 |
GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
GO:003083218 | Esophagus | ESCC | regulation of actin filament length | 112/8552 | 189/18723 | 1.13e-04 | 7.85e-04 | 112 |
GO:003083320 | Esophagus | ESCC | regulation of actin filament polymerization | 103/8552 | 172/18723 | 1.19e-04 | 8.15e-04 | 103 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:00018378 | Esophagus | ESCC | epithelial to mesenchymal transition | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LOX | insertion | In_Frame_Ins | novel | c.899_900insAAGATATCTCTGTTTTTTCACCTGTGAAACCATTCCTTCCTTCTGTTT | p.Glu300_Phe301insArgTyrLeuCysPhePheThrCysGluThrIleProSerPheCysLeu | p.E300_F301insRYLCFFTCETIPSFCL | P28300 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
LOX | SNV | Missense_Mutation | novel | c.1202G>A | p.Arg401His | p.R401H | P28300 | protein_coding | tolerated(0.66) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LOX | SNV | Missense_Mutation | c.1010N>A | p.Arg337Gln | p.R337Q | P28300 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
LOX | SNV | Missense_Mutation | c.49G>A | p.Ala17Thr | p.A17T | P28300 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
LOX | SNV | Missense_Mutation | novel | c.761N>C | p.Val254Ala | p.V254A | P28300 | protein_coding | tolerated(0.52) | benign(0.048) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LOX | SNV | Missense_Mutation | c.19G>A | p.Val7Met | p.V7M | P28300 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LOX | SNV | Missense_Mutation | c.842N>A | p.Arg281Gln | p.R281Q | P28300 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
LOX | SNV | Missense_Mutation | rs566461481 | c.364N>T | p.Arg122Cys | p.R122C | P28300 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LOX | SNV | Missense_Mutation | c.76G>A | p.Ala26Thr | p.A26T | P28300 | protein_coding | tolerated(0.61) | benign(0) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LOX | SNV | Missense_Mutation | c.842N>A | p.Arg281Gln | p.R281Q | P28300 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4015 | LOX | ENZYME, DRUGGABLE GENOME | inhibitor | 385612244 | ||
4015 | LOX | ENZYME, DRUGGABLE GENOME | inhibitor | 385612245 |
Page: 1 |